Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence?

Affiliations

¹ Goethe-University Frankfurt am Main, Frankfurt am Main, Germany claus.roedel@kgu.de.
² Goethe-University Frankfurt am Main, Frankfurt am Main, Germany.

Editorial

Claus Rödel et al. J Clin Oncol. 2014.

. 2014 Dec 1;32(34):3787-8.

doi: 10.1200/JCO.2014.58.5521. Epub 2014 Nov 3.

¹ Goethe-University Frankfurt am Main, Frankfurt am Main, Germany claus.roedel@kgu.de.
² Goethe-University Frankfurt am Main, Frankfurt am Main, Germany.

No abstract available

Comment on

Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Mak RH, et al. J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. J Clin Oncol. 2014. PMID: 25366678 Free PMC article.